Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20861336 | 0.81 | CYP11B2 (0.35) | CDK9KDM4EHTTCYP11B1CYP11B2 | |
| SCHEMBL24477989 | 0.80 | CYP11B1 (0.41) | CYP11B1CYP11B2 | |
| SCHEMBL18338614 | 0.80 | CDK9 (0.33) | CDK9 | |
| SCHEMBL20861570 | 0.77 | CDK9 (0.34) | CDK9 | |
| SCHEMBL20861567 | 0.77 | CYP11B2 (0.43) | CDK9CYP11B1CYP11B2 | |
| SCHEMBL19558405 | 0.77 | CDK9 (0.32) | CDK9 | |
| SCHEMBL18338588 | 0.71 | P2RX7 (0.33) | CDK9 | |
| SCHEMBL20861490 | 0.70 | DRD4 (0.37) | CDK9HTTKMT2ACYP11B1CYP11B2 | |
| SCHEMBL23107178 | 0.70 | DRD4 (0.37) | CDK9HTTKMT2ACYP11B1CYP11B2 | |
| SCHEMBL23107185 | 0.70 | DRD4 (0.37) | CDK9HTTKMT2ACYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352369-B2 | Pyridine and pyrimidine derivatives | ASTRAZENECA AB (SE) | 2022-06-07 | — | — | US | disclosed |
| US-20210171541-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2021-06-10 | — | — | US | disclosed |
| EP-3539961-A1 | POLYCYCLIC AMIDE DERIVATIVES AS CDK9 INHIBITORS | Astrazeneca AB (SE) | 2019-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171541-A1 | CHEMICAL COMPOUNDS | CDK9, BCL9, BCL9L | CDK9 1/4885KDM4E 489/4885HTT 2949/4885 |
| US-11352369-B2 | Pyridine and pyrimidine derivatives | CDK9, BCL9, CDK19 | CDK9 1/4885KDM4E 509/4885HTT 3024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.